A Risk Sciences International news item posted on June 22, 2021 and last updated on June 30, 2021

Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.

A recent study published by RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski in the journal JGH Open: An open access journal of gastroenterology and hepatology, has shown that only ciprofloxacin displayed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.

The research team concluded that further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.

The paper is available by clicking here.

More RSI News

Willhite receives prestigious SOT award

December 18, 2020

Calvin C. Willhite, an Associate Expert with Risk Sciences International working on a range of toxicological risk issues, was just announced as the recipient of the prestigious…

RSI gives keynote

October 31, 2020

RSI experts Jennifer Go and Daniel Krewski, were recently invited to present a paper on maternal and child environmental heath during a global, virtual workshop originating in Foshan, Guangdong, China.

RSI hosts Mitacs intern

September 7, 2020

Risk Sciences International will host Abdallah Alami as an intern in statistics with support from the Mitacs Accelerate program. This unique university-industry program supports interns at…

Dr. Mattison chairs NAM report

July 24, 2020

Compounded medications prepared by pharmacists or physicians have been used extensively throughout history as a mainstay of therapeutics.  Over the past half-century – with the…